Phase II Open-Label, Non-Randomized Trial of Cisplatin Chemotherapy in Patients With BRCA1-Positive Metastatic Breast Cancer
Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Tumor Response Rate
This is defined as the percentage of patients who achieved a complete response or partial response by RECIST criteria within the first six months.
Tomasz Byrski, MD, PhD
Pomenarian Medical University
Poland: Ministry of Health